SCHEMBL16010060

SCHEMBL16010060

O=C1O[C@H](COCc2ccccc2)C[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
PSEN1 P49768 4/20 0.46
PSEN2 P49810 4/20 0.46
APH1B Q8WW43 4/20 0.46
NCSTN Q92542 4/20 0.46
APH1A Q96BI3 4/20 0.46
PSENEN Q9NZ42 4/20 0.46
BCHE P06276 2/20 0.45
ACHE P22303 2/20 0.45
CTSV O60911 1/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
CTSC P53634 1/20 0.41
CTSF Q9UBX1 1/20 0.41
PDE4D Q08499 1/20 0.41
PTPN1 P18031 2/20 0.40
CDC25B P30305 1/20 0.40
AKT1 P31749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21697602 1.00 LMNA (0.51) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL21218201 0.87 LMNA (0.51) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL16018599 0.85 PSEN1 (0.47) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL16018622 0.85 PSEN1 (0.47) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL16018601 0.85 PSEN1 (0.47) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL524084 0.82 LMNA (0.58) LMNABCHEACHECTSVCTSL
SCHEMBL28102964 0.82 LMNA (0.58) LMNABCHEACHECTSVCTSL
SCHEMBL20107268 0.80 PSEN1 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20056422 0.79 PDE4D (0.42) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL20056463 0.78 LMNA (0.40) LMNAPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020129900-A1 METHOD FOR PRODUCING C-ARYLHYDROXY GLYCOXIDE DERIVATIVE 株式会社トクヤマ 2020-06-25 WO disclosed
EP-2968258-B1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-02-12 EP disclosed
EP-2968258-B1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-02-12 EP disclosed
EP-2968258-A1 DUAL SGLT1/SGLT2 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2016-01-20 EP disclosed
US-9012412-B2 Dual SGLT1/SGLT2 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-04-21 US disclosed
WO-2014164286-A1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-09 WO disclosed
US-20140256657-A1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256657-A1 DUAL SGLT1/SGLT2 INHIBITORS SLC5A1, SLC5A2, GLP1R LMNA 4631/4885PSEN1 3587/4885PSEN2 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.